NCT05038592 2026-04-14
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
44 trialsNCT02204085 2026-04-03
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT06930651 2026-03-11
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07389239 2026-02-20
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
Phase 1/2 Not yet recruiting
NCT02961101 2026-01-22
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT03661307 2026-01-12
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06383572 2025-12-23
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05089370 2025-12-08
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
University of Colorado, Denver
Phase 1/2 Active not recruiting
NCT06928662 2025-11-06
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06129734 2025-08-26
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT02650986 2025-06-17
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT02257138 2025-06-08
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT03709550 2022-10-05
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT02109744 2022-07-05
AML
University of Rochester
Phase 1/2 Completed
NCT05320640 2022-04-11
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01893320 2022-02-09
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03113071 2021-03-16
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT04553393 2020-12-04
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04493099 2020-11-12
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT01498445 2020-10-22
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04582604 2020-10-20
Ruxolitinib and Decitabine for High Risk Hematological Malignancies
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04337606 2020-04-07
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02921061 2020-03-17
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02951728 2020-03-11
DR-CHOP
Ruijin Hospital
Phase 1/2 Unknown
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01165996 2019-03-04
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02076191 2019-02-28
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01729845 2019-02-07
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00075010 2018-11-15
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00002831 2018-10-26
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02332889 2018-05-04
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
University of Louisville
Phase 1/2 Terminated
NCT02499861 2017-11-17
Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies
St. Justine's Hospital
Phase 1/2 Completed
NCT02316028 2017-10-27
DECIT
Universitair Ziekenhuis Brussel
Phase 1/2 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT00691938 2016-10-13
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Washington University School of Medicine
Phase 1/2 Completed
NCT01758367 2016-08-31
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01799083 2016-01-28
CIK
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01194908 2015-01-26
Re-expression of ER in Triple Negative Breast Cancers
Emory University
Phase 1/2 Terminated
NCT00477386 2014-09-25
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Indiana University
Phase 1/2 Completed
NCT00002832 2012-07-30
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed